Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20971223 | 0.88 | IP6K1 (0.57) | IP6K1MAPTL3MBTL1KCNH2SMN1; SMN2 | |
| SCHEMBL20971053 | 0.83 | SRC (0.55) | MAPTPKMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20971135 | 0.80 | MAPT (0.56) | MAPTPKMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29627442 | 0.78 | PARP1 (0.46) | IP6K1MAPTPKMSMN1; SMN2SRC | |
| SCHEMBL20971251 | 0.77 | SRC (0.40) | IP6K1MAPTPKMSRC | |
| SCHEMBL20971033 | 0.77 | POLB (0.41) | MAPTMCHR1PKMNPC1RAB9A | |
| SCHEMBL20971049 | 0.76 | MAPK9 (0.43) | IP6K1MAPTPKMNPC1RAB9A | |
| SCHEMBL29627431 | 0.76 | MAPK9 (0.43) | IP6K1MAPTPKMNPC1RAB9A | |
| SCHEMBL20971290 | 0.75 | MAPT (0.47) | MAPTNPC1RAB9ASRC | |
| SCHEMBL20971305 | 0.75 | MAPT (0.53) | MAPTPKMSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046681-B2 | Substituted piperidines for the treatment of cancer | LES LABORATOIRES SERVIER (FR) | 2021-06-29 | — | — | US | disclosed |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-05-19 | — | — | US | disclosed |
| EP-3468971-B1 | NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-02-19 | — | — | EP | disclosed |
| EP-3468974-B1 | NEW PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-02-12 | — | — | EP | disclosed |
| US-20190144449-A1 | (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-05-16 | — | — | US | disclosed |
| US-20190144448-A1 | PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144448-A1 | PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, BCL2, CASP3 | IP6K1 1851/4885MAPT 3150/4885MCHR1 4301/4885 |
| US-11046681-B2 | Substituted piperidines for the treatment of cancer | BCL2, MCL1, BCL2A1 | IP6K1 1871/4885MAPT 4497/4885MCHR1 4105/4885 |
| US-20190144449-A1 | (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, BCL2, CCNK | IP6K1 1108/4885MAPT 3232/4885MCHR1 4259/4885 |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CCNK | IP6K1 1108/4885MAPT 3232/4885MCHR1 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.